Stocks · News reference
Why Is Dermata Therapeutics Stock Gaining Thursday?
Dermata Therapeutics (DRMA) jumps 34% after positive clinical results for its weekly Bioneedle Tome Foundational Treatment.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dermata Therapeutics shares are trading higher after the company reported study results showing skin appearance improvements with its Tome Foundational Treatment.
Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic